Barclays PLC Atea Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 177,077 shares of AVIR stock, worth $564,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares

177,077

Previous 177,077 -0.0%

Holding current value

$564,875

Previous $593,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.17 - $4.02 $239,728 - $304,008	75,624 Added 74.54%	177,077 $593,000
Q2 2024 Aug 14, 2024	SELL	$3.31 - $4.04 $145,901 - $178,079	-44,079 Reduced 30.29%	101,453 $336,000
Q1 2024 May 15, 2024	SELL	$3.09 - $4.56 $159,304 - $235,090	-51,555 Reduced 26.16%	145,532 $588,000
Q4 2023 Feb 15, 2024	BUY	$2.8 - $3.35 $480,110 - $574,417	171,468 Added 669.3%	197,087 $601,000
Q3 2023 Nov 07, 2023	BUY	$3.0 - $3.79 $31,044 - $39,218	10,348 Added 67.76%	25,619 $77,000
Q2 2023 Aug 03, 2023	SELL	$3.21 - $5.06 $75,396 - $118,849	-23,488 Reduced 60.6%	15,271 $57,000
Q1 2023 May 04, 2023	BUY	$3.0 - $4.97 $38,031 - $63,004	12,677 Added 48.6%	38,759 $130,000
Q4 2022 Feb 13, 2023	SELL	$4.35 - $6.17 $47,593 - $67,505	-10,941 Reduced 29.55%	26,082 $126,000
Q3 2022 Nov 03, 2022	SELL	$5.49 - $8.79 $54,444 - $87,170	-9,917 Reduced 21.13%	37,023 $211,000
Q2 2022 Aug 12, 2022	SELL	$5.33 - $8.18 $80,323 - $123,272	-15,070 Reduced 24.3%	46,940 $333,000
Q1 2022 May 16, 2022	BUY	$5.5 - $9.19 $341,055 - $569,871	62,010 New	62,010 $448,000

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $266M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account